Dual Therapy for Complex Inflammatory Bowel Disease: Safety, Clinical and Steroid-Free Response
Objective Remission in patients with inflammatory bowel disease appears to plateau at 30–50% within the first year of biological monotherapy. Patients with Crohn’s disease (CD) and ulcerative colitis (UC) on monotherapy with biologics or small molecules may face this therapeutic ceiling, not reaching remission in relat...